![]() |
![]() | ![]() |
We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
![]()
A frustrating stock with a compelling story....2 F.D.A. approved drugs...a deep pipeline...substantial cash...intriguing collaborations with HGSI and Rockerfeller University in bacterial research...recently broke ground on $50. million manufacturing facility...a sales force of 56...''buy'' recommendation from Morgan Stanley stating MEDI is the best buy in its' price range...and the stock languishes at $14....Company reports that it never has been in better shape...Worth a look...
| ||||||||||||||
|
Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
© 2021 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News |